Guardian Pharmacy Services, Inc. (NYSE:GRDN – Get Free Report) has been given an average rating of “Moderate Buy” by the nine brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $43.8333.
GRDN has been the topic of a number of recent research reports. Zacks Research lowered shares of Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Truist Financial lifted their price target on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Weiss Ratings raised shares of Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, August 20th. Wall Street Zen raised shares of Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a research note on Sunday, August 9th. Finally, Oppenheimer raised their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th.
Read Our Latest Research Report on Guardian Pharmacy Services
Institutional Inflows and Outflows
Guardian Pharmacy Services Stock Up 0.7%
Shares of NYSE:GRDN opened at $37.56 on Thursday. Guardian Pharmacy Services has a 52-week low of $23.14 and a 52-week high of $47.02. The stock’s fifty day simple moving average is $40.10 and its 200-day simple moving average is $37.86. The company has a market capitalization of $1.87 billion, a P/E ratio of 36.47, a P/E/G ratio of 1.93 and a beta of 0.10.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. On average, sell-side analysts anticipate that Guardian Pharmacy Services will post 1.19 earnings per share for the current year.
Guardian Pharmacy Services Company Profile
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.
Recommended Stories
- Five stocks we like better than Guardian Pharmacy Services
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
